Status and prospects of percutaneous vertebroplasty combined with ¹²⁵I seed implantation for the treatment of spinal metastases.

Lin Xie, Yanjin Chen, Ya Zhang, Zuozhang Yang, Zhaoxin Zhang, Lida Shen, Zhongqin Yuan, Mingyan Ren

Journal: World journal of surgical oncology 2016;13():119

PMID: 25886442

Free Full Text on BioMed Central View on PubMed

Abstract

Metastatic spinal tumours are the most common type of bone metastasis. Various methods have been used to treat metastatic spinal lesions, including radiotherapy, chemotherapy, isotope therapy, bisphosphonate therapy, analgesics, and surgery. Conservative treatments such as radiotherapy and chemotherapy are not appropriate and usually are ineffective in patients with vertebral fractures and/or spinal instability. Minimally invasive surgical treatments using non-vascular interventional technology, such as percutaneous vertebroplasty (PVP), have been successfully performed in the clinical setting. PVP is a non-invasive procedure that creates small wounds and is usually associated with only minor complications. In the present study, we will review the clinical status and prospects for the use PVP combined with (125)I seed implantation (PVPI) to treat spinal metastases. The scientific evidence for this treatment, including safety, efficacy, and outcome measures, as well as comparisons with other therapies, was analysed in detail. PVPI effectively alleviates pain in metastatic spinal tumour patients, and the use of interstitial (125)I seed implants can enhance the clinical outcomes. In conclusion, PVPI is a safe, reliable, effective, and minimally invasive treatment. The techniques of PVP and (125)I seed implantation complement each other and strengthen the treatment's effect, presenting a new alternative treatment for spinal metastases with potentially wide application.

Address: Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].; Department of Medical Oncology, Bone and Soft Tissue Tumours Research Centre of Yunnan Province, Third Affiliated Hospital of Kunming Medical University, Tumour Hospital of Yunnan Province, Kunming, Yunnan, 650118, PR China. [email protected].

DOI: 10.1186/s12957-015-0484-y

Link outs

Free resources

Full Text Sources:

Other Literature Sources:

https://scite.ai/reports/25886442

MeSH Terms: Combined Modality Therapy, Humans, Iodine Radioisotopes, Neoplasm Seeding, Prognosis, Spinal Neoplasms, Vertebroplasty